JP2013542185A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013542185A5 JP2013542185A5 JP2013528356A JP2013528356A JP2013542185A5 JP 2013542185 A5 JP2013542185 A5 JP 2013542185A5 JP 2013528356 A JP2013528356 A JP 2013528356A JP 2013528356 A JP2013528356 A JP 2013528356A JP 2013542185 A5 JP2013542185 A5 JP 2013542185A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- polypeptide
- transcription
- factor
- high mobility
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 60
- 229920001184 polypeptide Polymers 0.000 claims description 55
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 55
- 102000004169 proteins and genes Human genes 0.000 claims description 48
- 108090000623 proteins and genes Proteins 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 35
- 230000000813 microbial effect Effects 0.000 claims description 25
- 230000002401 inhibitory effect Effects 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- 102100022128 High mobility group protein B2 Human genes 0.000 claims description 11
- 102100022130 High mobility group protein B3 Human genes 0.000 claims description 11
- 102100022124 High mobility group protein B4 Human genes 0.000 claims description 11
- 101001045791 Homo sapiens High mobility group protein B2 Proteins 0.000 claims description 11
- 101001045794 Homo sapiens High mobility group protein B3 Proteins 0.000 claims description 11
- 101001045782 Homo sapiens High mobility group protein B4 Proteins 0.000 claims description 11
- 230000027455 binding Effects 0.000 claims description 9
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 4
- 230000000890 antigenic effect Effects 0.000 claims description 4
- 108090000144 Human Proteins Proteins 0.000 claims description 3
- 102000003839 Human Proteins Human genes 0.000 claims description 3
- 239000004599 antimicrobial Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 244000005700 microbiome Species 0.000 claims description 2
- 102000040945 Transcription factor Human genes 0.000 claims 30
- 108091023040 Transcription factor Proteins 0.000 claims 24
- 102000004857 Lymphoid enhancer-binding factor 1 Human genes 0.000 claims 12
- 108090001093 Lymphoid enhancer-binding factor 1 Proteins 0.000 claims 12
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 12
- 102000008685 T Cell Transcription Factor 1 Human genes 0.000 claims 12
- 108010088184 T Cell Transcription Factor 1 Proteins 0.000 claims 12
- 230000035897 transcription Effects 0.000 claims 12
- 238000013518 transcription Methods 0.000 claims 12
- 101100489922 Caenorhabditis elegans abf-2 gene Proteins 0.000 claims 6
- 108010077544 Chromatin Proteins 0.000 claims 6
- 101000798109 Homo sapiens Melanotransferrin Proteins 0.000 claims 6
- 101000967073 Homo sapiens Metal regulatory transcription factor 1 Proteins 0.000 claims 6
- 101001030197 Homo sapiens Myelin transcription factor 1 Proteins 0.000 claims 6
- 101000809045 Homo sapiens Nucleolar transcription factor 1 Proteins 0.000 claims 6
- 101100346698 Hypocrea jecorina lxr1 gene Proteins 0.000 claims 6
- 102100032239 Melanotransferrin Human genes 0.000 claims 6
- 102100038485 Nucleolar transcription factor 1 Human genes 0.000 claims 6
- 102000017143 RNA Polymerase I Human genes 0.000 claims 6
- 108010013845 RNA Polymerase I Proteins 0.000 claims 6
- 108010013721 SOX Transcription Factors Proteins 0.000 claims 6
- 102000017100 SOX Transcription Factors Human genes 0.000 claims 6
- 101000997749 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Intrastrand cross-link recognition protein Proteins 0.000 claims 6
- 210000003483 chromatin Anatomy 0.000 claims 6
- 230000002538 fungal effect Effects 0.000 claims 6
- 230000013011 mating Effects 0.000 claims 6
- 230000002438 mitochondrial effect Effects 0.000 claims 6
- 230000010076 replication Effects 0.000 claims 6
- 230000020509 sex determination Effects 0.000 claims 6
- 230000014639 sexual reproduction Effects 0.000 claims 6
- 108010040073 transcription factor UBF Proteins 0.000 claims 6
- 108020004414 DNA Proteins 0.000 claims 5
- 230000000845 anti-microbial effect Effects 0.000 claims 2
- 230000004568 DNA-binding Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 230000001323 posttranslational effect Effects 0.000 claims 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 24
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 24
- 239000012634 fragment Substances 0.000 description 22
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 description 9
- 108700010013 HMGB1 Proteins 0.000 description 9
- 101150021904 HMGB1 gene Proteins 0.000 description 9
- 102100037907 High mobility group protein B1 Human genes 0.000 description 9
- 230000028993 immune response Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000004053 dental implant Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- -1 stents Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38137710P | 2010-09-09 | 2010-09-09 | |
| US61/381,377 | 2010-09-09 | ||
| PCT/US2011/051107 WO2012034090A1 (en) | 2010-09-09 | 2011-09-09 | Compositions and methods for the removal of biofilms |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015193476A Division JP2016000760A (ja) | 2010-09-09 | 2015-09-30 | バイオフィルムを除去するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013542185A JP2013542185A (ja) | 2013-11-21 |
| JP2013542185A5 true JP2013542185A5 (enExample) | 2014-09-25 |
| JP6012603B2 JP6012603B2 (ja) | 2016-10-25 |
Family
ID=44654515
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013528356A Active JP6012603B2 (ja) | 2010-09-09 | 2011-09-09 | バイオフィルムを除去するための組成物および方法 |
| JP2015193476A Withdrawn JP2016000760A (ja) | 2010-09-09 | 2015-09-30 | バイオフィルムを除去するための組成物および方法 |
| JP2017122250A Active JP6420417B2 (ja) | 2010-09-09 | 2017-06-22 | バイオフィルムを除去するための組成物および方法 |
| JP2018081136A Withdrawn JP2018111731A (ja) | 2010-09-09 | 2018-04-20 | バイオフィルムを除去するための組成物および方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015193476A Withdrawn JP2016000760A (ja) | 2010-09-09 | 2015-09-30 | バイオフィルムを除去するための組成物および方法 |
| JP2017122250A Active JP6420417B2 (ja) | 2010-09-09 | 2017-06-22 | バイオフィルムを除去するための組成物および方法 |
| JP2018081136A Withdrawn JP2018111731A (ja) | 2010-09-09 | 2018-04-20 | バイオフィルムを除去するための組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20120128701A1 (enExample) |
| EP (1) | EP2613797B1 (enExample) |
| JP (4) | JP6012603B2 (enExample) |
| AU (1) | AU2011299025B2 (enExample) |
| CA (1) | CA2810851C (enExample) |
| WO (1) | WO2012034090A1 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9457077B2 (en) | 2009-11-18 | 2016-10-04 | Katherine Rose Kovarik | Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases |
| US9585920B2 (en) | 2011-02-04 | 2017-03-07 | Katherine Rose Kovarik | Method and system for treating cancer cachexia |
| WO2011123396A1 (en) * | 2010-03-29 | 2011-10-06 | University Of Southern California | Compositions and methods for the removal of biofilms |
| AU2011299025B2 (en) * | 2010-09-09 | 2015-07-09 | Nationwide Children's Hospital, Inc. | Compositions and methods for the removal of biofilms |
| US11998479B2 (en) | 2011-02-04 | 2024-06-04 | Seed Health, Inc. | Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure |
| US12279989B2 (en) | 2011-02-04 | 2025-04-22 | Seed Health, Inc. | Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity |
| US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
| US12257272B2 (en) | 2015-12-24 | 2025-03-25 | Seed Health, Inc. | Method and system for reducing the likelihood of developing depression in an individual |
| US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
| US10940169B2 (en) | 2015-11-30 | 2021-03-09 | Joseph E. Kovarik | Method for reducing the likelihood of developing cancer in an individual human being |
| US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
| US10314865B2 (en) | 2011-02-04 | 2019-06-11 | Katherine Rose Kovarik | Method and system for treating cancer and other age-related diseases by extending the healthspan of a human |
| US9730967B2 (en) | 2011-02-04 | 2017-08-15 | Katherine Rose Kovarik | Method and system for treating cancer cachexia |
| US11274144B2 (en) | 2013-06-13 | 2022-03-15 | Research Institute At Nationwide Children's Hospital | Compositions and methods for the removal of biofilms |
| JP2016521752A (ja) * | 2013-06-13 | 2016-07-25 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | Ｂｕｒｋｈｏｌｄｅｒｉａ感染の処置のための組成物および方法 |
| US9745366B2 (en) | 2013-09-23 | 2017-08-29 | University Of Southern California | Compositions and methods for the prevention of microbial infections |
| US11248040B2 (en) | 2013-09-26 | 2022-02-15 | Trellis Bioscience, Llc | Binding moieties for biofilm remediation |
| US10233234B2 (en) | 2014-01-13 | 2019-03-19 | Trellis Bioscience, Llc | Binding moieties for biofilm remediation |
| US11969445B2 (en) | 2013-12-20 | 2024-04-30 | Seed Health, Inc. | Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH |
| US11672835B2 (en) | 2013-12-20 | 2023-06-13 | Seed Health, Inc. | Method for treating individuals having cancer and who are receiving cancer immunotherapy |
| US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
| US11642382B2 (en) | 2013-12-20 | 2023-05-09 | Seed Health, Inc. | Method for treating an individual suffering from bladder cancer |
| US11213552B2 (en) | 2015-11-30 | 2022-01-04 | Joseph E. Kovarik | Method for treating an individual suffering from a chronic infectious disease and cancer |
| US12329783B2 (en) | 2013-12-20 | 2025-06-17 | Seed Health, Inc. | Method and system to improve the health of a person's skin microbiome |
| US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
| US11998574B2 (en) | 2013-12-20 | 2024-06-04 | Seed Health, Inc. | Method and system for modulating an individual's skin microbiome |
| US12246043B2 (en) | 2013-12-20 | 2025-03-11 | Seed Health, Inc. | Topical application to treat acne vulgaris |
| US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
| US11980643B2 (en) | 2013-12-20 | 2024-05-14 | Seed Health, Inc. | Method and system to modify an individual's gut-brain axis to provide neurocognitive protection |
| US11026982B2 (en) | 2015-11-30 | 2021-06-08 | Joseph E. Kovarik | Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being |
| US12005085B2 (en) | 2013-12-20 | 2024-06-11 | Seed Health, Inc. | Probiotic method and composition for maintaining a healthy vaginal microbiome |
| US11529379B2 (en) | 2013-12-20 | 2022-12-20 | Seed Health, Inc. | Method and system for reducing the likelihood of developing colorectal cancer in an individual human being |
| EP3113630B1 (en) | 2014-03-06 | 2019-12-11 | The Research Institute at Nationwide Children's Hospital | Probiotic formulations and methods for use |
| US10624934B2 (en) | 2014-03-06 | 2020-04-21 | Research Institute At Nationwide Children's Hospital | Prebiotic formulations |
| WO2016154491A1 (en) * | 2015-03-25 | 2016-09-29 | Trellis Bioscience, Llc | Binding moieties for biofilm remediation |
| US20180207067A1 (en) | 2015-07-14 | 2018-07-26 | Research Institute at Nationwide Children's Hospit al | Novel formulation for the elimination of cariogenic and opportunistic pathogens within the oral cavity |
| HK1255383A1 (zh) | 2015-07-31 | 2019-08-16 | The Research Institute At Nationwide Children's Hospital | 去除生物膜的肽及抗體 |
| WO2017066719A2 (en) | 2015-10-14 | 2017-04-20 | Research Institute At Nationwide Children's Hospital | Hu specific interfering agents |
| EP3565589A1 (en) | 2017-01-04 | 2019-11-13 | Research Institute at Nationwide Children's Hospital | Dnabii vaccines and antibodies with enhanced activity |
| WO2018129092A1 (en) | 2017-01-04 | 2018-07-12 | Research Institute At Nationwide Children's Hospital | Antibody fragments for the treatment of biofilm-related disorders |
| BR112019014921A2 (pt) | 2017-01-27 | 2020-03-31 | StemRIM Inc. | Agente terapêutico para miocardiopatia, infarto antigo do miocárdio e insuficiência cardíaca crônica |
| EP3595445B1 (en) * | 2017-03-15 | 2024-09-04 | The Research Institute at Nationwide Children's Hospital | Composition and methods for disruption of bacterial biofilms without accompanying inflammation |
| EP3719117A4 (en) | 2017-12-01 | 2021-11-03 | Stemrim Inc. | EECTODERMAL MESENCHYMAL STEM CELLS AND METHOD FOR PRODUCING THEM |
| US11298403B2 (en) | 2017-12-01 | 2022-04-12 | StemRIM Inc. | Therapeutic agent for inflammatory bowel disease |
| US20210024594A1 (en) | 2018-02-08 | 2021-01-28 | StemRIM Inc. | Therapeutic Agent for Psoriasis |
| JP6641420B2 (ja) | 2018-06-12 | 2020-02-05 | 株式会社アマダホールディングス | 分割金型の装着方法及びプレスブレーキ |
| WO2019241177A1 (en) * | 2018-06-12 | 2019-12-19 | Terumo Cardiovascular Systems Corporation | Circular retractor for cardiovascular valve procedures |
| EP3860718A4 (en) | 2018-10-05 | 2022-08-31 | Research Institute at Nationwide Children's Hospital | HMGB1 PROTEIN DERIVATIVES FOR BIOFILM REMOVAL |
| US12304933B2 (en) | 2018-10-05 | 2025-05-20 | StemRIM Inc. | Disease treatment drug based on mesenchymal-stem-cell mobilization |
| US12453747B2 (en) | 2019-06-03 | 2025-10-28 | Research Institute At Nationwide Children's Hospital | Prebiotic formulations for prevention of sepsis and necroenterocolitis induced neurodevelopmental deficiencies |
| BR112021026890A2 (pt) | 2019-07-08 | 2022-03-15 | Res Inst Nationwide Childrens Hospital | Composições de anticorpo para interromper biofilmes |
| WO2025106896A1 (en) * | 2023-11-17 | 2025-05-22 | Rush University Medical Center | Coating of medical and implant biomaterials with an anti-biofilm agent to prevent and treat infection |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US20050131222A1 (en) | 1995-04-21 | 2005-06-16 | Human Genome Sciences, Inc. | Nucleotide sequence of the haemophilus influenzae Rd genome, fragments thereof, and uses thereof |
| US6355450B1 (en) | 1995-04-21 | 2002-03-12 | Human Genome Sciences, Inc. | Computer readable genomic sequence of Haemophilus influenzae Rd, fragments thereof, and uses thereof |
| US6303321B1 (en) * | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
| US20020132753A1 (en) * | 2000-01-31 | 2002-09-19 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
| AU2002367953C1 (en) | 2001-05-04 | 2009-02-19 | Paratek Pharmaceuticals, Inc | Transcription factor modulating compounds and methods of use thereof |
| HUP0500042A3 (en) * | 2001-05-15 | 2010-01-28 | Long Island Jewish Res Inst | Use of hmg fragments as anti-inflammatory agents |
| EP1421108A2 (en) | 2001-08-24 | 2004-05-26 | Micrologix Biotech, Inc. | Antimicrobial and anti-inflammatory peptides |
| ITMI20011986A1 (it) * | 2001-09-25 | 2003-03-25 | San Raffaele Centro Fond | Metodo e composizione per l'attivazione di cellule presentanti l'antigene |
| US20030099602A1 (en) | 2001-10-25 | 2003-05-29 | Levin Gilbert V. | D-tagatose as an anti-biofilm agent |
| DK2255826T3 (en) | 2002-08-02 | 2016-06-20 | Glaxosmithkline Biologicals Sa | Neisserial vaccine compositions comprising a combination of antigens. |
| GB0226251D0 (en) * | 2002-11-11 | 2002-12-18 | San Raffaele Centro Fond | Acetylated protein |
| AU2003295653B2 (en) * | 2002-11-20 | 2007-08-16 | The Feinstein Institute Of Medical Research | Use of HMGB polypeptides for increasing immune responses |
| JP4754219B2 (ja) | 2002-12-02 | 2011-08-24 | アムジエン・フレモント・インコーポレイテツド | 腫瘍壊死因子を対象とする抗体、およびそれらの使用 |
| WO2004061456A2 (de) * | 2003-01-03 | 2004-07-22 | Alcedo Biotech Gmbh | Verwendungen von hmgb, hmgn, hmga proteinen |
| WO2004062583A2 (en) | 2003-01-07 | 2004-07-29 | University Of Iowa Research Foundation | Vaccine and method for preventing biofilm formation |
| WO2004072094A2 (en) * | 2003-02-14 | 2004-08-26 | Fondazione Centro San Raffaele Del Monte Tabor | Hmgb1 modulator binding domain |
| JP2006519605A (ja) | 2003-03-06 | 2006-08-31 | チルドレンズ ホスピタル， インコーポレイテッド | 類型不能ｈａｅｍｏｐｈｉｌｕｓｉｎｆｌｕｅｎｚａｅの中耳炎単離株の遺伝子 |
| WO2005025604A2 (en) * | 2003-09-10 | 2005-03-24 | The General Hospital Corporation | Use of hmgb and hmgb fragments to decrease specific immune response |
| US20090029929A1 (en) | 2004-03-26 | 2009-01-29 | Locomogene, Inc. | Decoy Nucleic Acid to Synoviolin Gene Promoter |
| US20080305120A1 (en) * | 2004-06-17 | 2008-12-11 | Medimmune, Inc. | Immunogenic Compositions Comprising Hmgb 1 Polypeptides |
| CA2578478A1 (en) | 2004-08-06 | 2006-02-16 | National Jewish Medical And Research Center | Product and process for inhibition of biofilm development |
| WO2007001422A2 (en) | 2004-10-22 | 2007-01-04 | Medimmune, Inc. | High affinity antibodies against hmgb1 and methods of use thereof |
| US20060228384A1 (en) | 2005-04-06 | 2006-10-12 | Sequoia Sciences, Inc. | Control of biofilm with a biofilm inhibitor |
| WO2006114805A2 (en) * | 2005-04-28 | 2006-11-02 | Fondazione Centro San Raffaele Del Monte Tabor | Use of hmgb2 and hmgb3 proteins for medical applications |
| US20090264342A1 (en) | 2006-02-13 | 2009-10-22 | Trustees Of Boston University | Compositions and methods for antibiotic potentiation and drug discovery |
| EP2061886B1 (en) | 2006-08-21 | 2014-05-07 | The University Of British Columbia | Small cationic immunomodulatory peptides |
| EP1980269A1 (en) | 2007-04-13 | 2008-10-15 | Katholieke Universiteit Leuven | Prevention of staphylococcus biofilm formation |
| WO2011123396A1 (en) * | 2010-03-29 | 2011-10-06 | University Of Southern California | Compositions and methods for the removal of biofilms |
| AU2011299025B2 (en) | 2010-09-09 | 2015-07-09 | Nationwide Children's Hospital, Inc. | Compositions and methods for the removal of biofilms |
| JP2016521752A (ja) | 2013-06-13 | 2016-07-25 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | Ｂｕｒｋｈｏｌｄｅｒｉａ感染の処置のための組成物および方法 |
| US9745366B2 (en) | 2013-09-23 | 2017-08-29 | University Of Southern California | Compositions and methods for the prevention of microbial infections |
-
2011
- 2011-09-09 AU AU2011299025A patent/AU2011299025B2/en active Active
- 2011-09-09 US US13/229,575 patent/US20120128701A1/en not_active Abandoned
- 2011-09-09 JP JP2013528356A patent/JP6012603B2/ja active Active
- 2011-09-09 WO PCT/US2011/051107 patent/WO2012034090A1/en not_active Ceased
- 2011-09-09 CA CA2810851A patent/CA2810851C/en active Active
- 2011-09-09 EP EP11758346.8A patent/EP2613797B1/en active Active
-
2015
- 2015-09-30 JP JP2015193476A patent/JP2016000760A/ja not_active Withdrawn
- 2015-10-16 US US14/885,800 patent/US10595530B2/en active Active
-
2017
- 2017-06-22 JP JP2017122250A patent/JP6420417B2/ja active Active
-
2018
- 2018-04-20 JP JP2018081136A patent/JP2018111731A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013542185A5 (enExample) | ||
| JP2017158561A5 (enExample) | ||
| JP2019526611A5 (enExample) | ||
| JP2014519333A5 (enExample) | ||
| BR0316082A (pt) | Métodos de tratar ou prevenir e de controlar uma doença mieloproliferative, de reduzir ou evitar um efeito adverso associado com a administração de um segundo agente ativo em um paciente sofrendo de uma doença mieloproliferativa e de aumentar a eficácia terapêutica de um tratamento de doenças mieloproliferativa, composição farmacêutica e kit | |
| BR0309837A (pt) | Forma de administração trans-epicutânea para tratamento da sìndrome das pernas inquietas | |
| BRPI0514420A (pt) | peptìdeo, variante do mesmo, ou um sal farmaceuticamente aceitável do mesmo, composição, uso de um peptìdeo ou de uma variante de peptìdeo, substrato, e, métodos de tratamento ou prevenção de um infecção microbiana, e de tratamento de uma ferida em um indivìduo | |
| MA32539B1 (fr) | Traitement du diabète chez des patients pour lesquels une thérapie par la metformine n'est pas appropriée | |
| JP2018512454A5 (enExample) | ||
| BR112014027010A2 (pt) | uso de laquinimod de alta dose para tratamento de esclerose múltipla | |
| EP4059570A1 (en) | Compositions and methods for treating allergic inflammatory conditions | |
| JP2021504390A5 (enExample) | ||
| WO2010124283A4 (en) | Methods and compositions relating to hematologic malignancies | |
| JP2017526627A5 (enExample) | ||
| JPWO2019156137A5 (enExample) | ||
| JP4234439B2 (ja) | Ｉｌ−１２発現調節剤 | |
| MX2014002471A (es) | Combinaciones sinergicas de los inhibidores de p13k y mek. | |
| RU2010142456A (ru) | Синергические комбинации 5'-метилтиоаденозина | |
| CL2024003601A1 (es) | Nuevas combinaciones terapéuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| TWI351950B (en) | Use of (halobenzyloxy) benzylamino-propanamides fo | |
| Zhang et al. | Noval advance of histone modification in inflammatory skin diseases and related treatment methods | |
| JP4290764B2 (ja) | ヒトおよび動物のボルナ病ウイルスへの感染防止、ならびに情動障害およびｂｄｖ感染に関連するその他の障害の予防および治療に対するアダマンタンアミンまたはその構造的類縁化合物の使用 | |
| Krämer et al. | Bruton tyrosine kinase inhibitors in multiple sclerosis: evidence and expectations | |
| US20190298802A1 (en) | Small peptide compositions and uses thereof | |
| JP2009500045A5 (enExample) |